Herantis Pharma Oyj
OTC: HRPMF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Antti Vuolanto D.Sc. (Tech)
- Employees
- 10
- Headquarters
- Espoo, Finland
- IPO year
- 2018
- Market cap
- $59.5M
- Website
- https://www.herantis.com
Loading HRPMF…
Loading profile data…Frequently asked questions about HRPMF
What does Herantis Pharma Oyj (HRPMF) do?
Herantis Pharma Oyj, a biotechnology enterprise, specializes in creating disease-modifying therapies for Parkinson's disease (PD) that harness Cerebral Dopamine Neurotrophic Factor (CDNF). Central to its developmental efforts is HER-096, a sophisticated, compact, synthetic chemical peptidomimetic originating from the active parent molecule. This...
Where does HRPMF trade?
Herantis Pharma Oyj (HRPMF) trades on the Other OTC.
What sector is HRPMF in?
Herantis Pharma Oyj (HRPMF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Herantis Pharma Oyj?
Antti Vuolanto D.Sc. (Tech) is the chief executive officer of Herantis Pharma Oyj (HRPMF).
Where is Herantis Pharma Oyj headquartered?
Herantis Pharma Oyj is headquartered in Finland.
Does HRPMF pay a dividend?
Herantis Pharma Oyj (HRPMF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did HRPMF go public?
Herantis Pharma Oyj (HRPMF) completed its initial public offering in 2018.